Maria A Argiriadi

USPTO Granted Patents = 15 (Patent Applications = 15)

CIPO Patents = 5 (Patent Applications = 6)

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 10.6

ph-index = 6

Forward Citations = 372(Granted Patents)

Location History:

Wayland, MA (US) (2011 - 2017)
Southboro, MA (US) (2019)
Southborough, MA (US) (2018 - 2022)
Worcester, MA (US) (2023)

Company Filing History:

Abbott Laboratories Corporation

patents

1 out of 832,680

Other

patents

Years Active: 2011-2023

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11767310 - Nicotinamide RIPK1 inhibitors (2023-09-26),

2. 11344621 - Interleukin-13 binding proteins (2022-05-31),

3. 10508113 - Inhibitors of tyrosine kinase 2 mediated signaling (2019-12-17),

4. 10160748 - Indazolones as modulators of tnf signaling (2018-12-25),

5. 10106501 - Nuclear receptor modulators (2018-10-23),

6. 10093733 - LRP-8 binding dual variable domain immunoglobulin proteins (2018-10-09),

7. 10086076 - Interleukin-13 binding proteins (2018-10-02),

8. 9592293 - Interleukin-13 binding proteins (2017-03-14),

9. 9365579 - Tricyclic compounds (2016-06-14),

10. 9115151 - Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof (2015-08-25),

11. 8962629 - Tricyclic compounds (2015-02-24),

12. 8785639 - Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof (2014-07-22),

13. 8604177 - Interleukin-13 binding proteins (2013-12-10),

14. 8008481 - Indazole compounds (2011-08-30),

15. 7915388 - Interleukin-13 binding proteins (2011-03-29),

Title: Maria A Argiriadi: Pioneering Innovations in Pharmaceuticals

Introduction:

Maria A Argiriadi, a distinguished inventor based in Wayland, MA, US, has made remarkable contributions to the world of inventions through her dedication to innovation and relentless pursuit of excellence. With 15 patents to her name, Maria's work serves as a beacon of inspiration for future generations of inventors, urging them to push the boundaries of what is achievable in the field of science and technology.

Latest Patents:

Maria's latest patents include groundbreaking innovations in the pharmaceutical realm. One of her recent patents involves Nicotinamide RIPK1 inhibitors, which are compounds designed to inhibit RIPK1 and are crucial in the treatment of conditions like Ulcerative Colitis. Additionally, Maria has developed Interleukin-13 binding proteins, specifically antibodies with high affinity for hIL-13, capable of neutralizing its activity both in vitro and in vivo.

Career Highlights:

Throughout her illustrious career, Maria has demonstrated a keen understanding of pharmaceutical research and development. Her pioneering work in designing novel compounds and antibodies showcases her commitment to advancing the field of medicine. Maria's contributions have not only enhanced the treatment options available but have also opened new avenues for therapeutic interventions in various disorders.

Collaborations:

Maria has collaborated with esteemed professionals in the industry, including Richard W Dixon and Michael M Friedman. Working alongside such talented individuals has enriched her projects, leading to the successful development and commercialization of innovative pharmaceutical solutions. Collaborative efforts have been key to Maria's success in bringing her inventions to fruition.

Conclusion:

In conclusion, Maria A Argiriadi's remarkable journey as an inventor exemplifies the power of unwavering dedication and passion for innovation. Her patents stand as a testament to her ingenuity and relentless pursuit of excellence in the pharmaceutical realm. Maria's work continues to inspire and pave the way for future inventors to break barriers and shape the future of science and technology.

This text is generated by artificial intelligence and may not be accurate.